Immunovant Inc.

NASDAQ: IMVT · Real-Time Price · USD
15.01
-0.19 (-1.25%)
At close: Aug 15, 2025, 3:13 PM

Immunovant Income Statement

Financials in USD. Fiscal year is April - March.
Fiscal Year FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Mar 31, 2025 Mar 31, 2024 Mar 31, 2023 Mar 31, 2022 Mar 31, 2021
Revenue
n/a n/a n/a n/a n/a
Cost of Revenue
377K 231K 1.32M 1.23M 998K
Gross Profit
-377K -231K -1.32M -1.23M -998K
Operating Income
-438.15M -282.71M -198.47M -156.16M -107.79M
Interest Income
24.73M 24.95M 7.58M n/a n/a
Pretax Income
-412.95M -258.77M -210.95M -156.81M -107.79M
Net Income
-413.84M -259.34M -210.96M -156.73M -107.43M
Selling & General & Admin
77.23M 57.28M 48.02M 54.23M 39.51M
Research & Development
360.92M 225.43M 160.26M 101.81M 68.6M
Other Expenses
n/a n/a -253K -781K 328K
Operating Expenses
438.15M 282.71M 208.28M 156.03M 108.12M
Interest Expense
n/a n/a 12.48M 655K n/a
Selling & Marketing Expenses
n/a n/a n/a n/a n/a
Cost & Expenses
438.15M 282.71M 208.28M 156.03M 108.12M
Income Tax Expense
891K 567K 9K -84K -358K
Shares Outstanding (Basic)
151.57M 138.1M 123.08M 109.68M 87.76M
Shares Outstanding (Diluted)
151.57M 138.1M 123.08M 109.68M 87.76M
EPS (Basic)
-2.73 -1.88 -1.71 -1.43 -1.22
EPS (Diluted)
-2.73 -1.88 -1.71 -1.43 -1.22
EBITDA
-412.57M -269.98M -209.63M -155.58M -106.79M
EBIT
-412.95M -270.21M -210.95M -156.81M -107.79M
Depreciation & Amortization
377K 231K 1.32M 1.23M 998K